Breaking Research News from sources other than Breastcancer.org

1…6791112…104

Comments

  • marijen
    marijen
    edited May 2018

    You’re welcome Zarovka, thank you for your comments.

    Heidihill, I like your comments too. On inflammation - why we need to fight it: from www.envita.com.

    Envita is a very honest website. They go into detail on why we’re not getting the best treatments, including insurance companies, medicare, doctor education and more.

    ——————————————-

    Chronic Inflammation

    In Latin, the word "inflammation" means "I ignite, set alight" and like gasoline, that's exactly what it does to cancer. A microenvironment of chronic inflammation can increase the risk of cancer, bolster chemotherapy resistance and turn on oncogenes, genes that can turn cells into tumors.

    Inflammation can become chronic if the cause of the inflammation persists or certain control mechanisms in charge of shutting down the process fail. When these inflammatory responses become chronic, cell mutation and proliferation can result, often creating an environment that is conducive to the development of cancer. The so-called "perfect storm" is an extreme challenge that cancer patients face.


    · Share on Facebook
  • marijen
    marijen
    edited May 2018

    Common drug may help battle aggressive breast cancer

    Published Saturday 5 May 2018

    By Tim Newman

    Fact checked by Jasmin Collier

    Basal-like breast cancer affects women at a relatively young age and is challenging to treat. The discovery that a common drug for osteoporosis may halt its progress is welcome news.New research offers a potential avenue for the treatment of basal-like breast cancer.Basal-like breast cancer develops in younger women, and prognosis rates are the worst of any cancertype.Often caught at a late stage, the tumors are normally aggressive and spread quickly.Even when treatment is successful, basal-like breast cancer is more likely to recur and metastasize than other types.The reason why this type of cancer is so hard to treat is that the three major targets for therapy are not usually present. In these cases, it is referred to as triple-negative breast cancer.The vast majority of breast cancer drugs target estrogen receptors, progesterone receptors, or the hormone epidermal growth factor receptor 2. In about 10–20 percent of breast cancer cases, they are not present — but without them, most therapeutics have no teeth.New study-co author Prof. Chenfang Dong, from the Zhejiang University School of Medicine in Hangzhou, China, reiterates why research into this type of cancer is so pressing:"The highly aggressive nature and the absence of effective therapeutics for basal-like breast cancer make it a high priority to elucidate what determines its aggressiveness and identify potential therapeutic targets."Details of his latest study were published recently in the Journal of Experimental Medicine.
    · Share on Facebook
  • Sara536
    Sara536
    edited May 2018

    I suspect that plenty of patients have been lowering dosages of prescribed medication for years (without telling their doctors). I know my mother did. She did not have cancer but she routinely chopped her various pills in half or quarters. Her doctors just didn’t seem to understand that it didn’t make sense to give a frail 93 year old the same amount as a young person weighing twice as much.

    · Share on Facebook
  • Hopeful82014
    Hopeful82014
    edited May 2018

    This isn't research per se but is something that should concern ALL of us, whether in the US or otherwise, since there may be a ripple effect in terms of support for research, etc.

    Breast Cancer Info Scrubbed From Government Website

    https://www.medscape.com/viewarticle/894784?src=WNL_infoc_180510_MSCPEDIT_TEMP2&uac=153476CT&impID=1627592&faf=1

    · Share on Facebook
  • zarovka
    zarovka
    edited May 2018

    Sara - I know that is true. Doesn't work with IV chemo unfortunately. However, we as always have the right to say no to treatment...

    Will be trying to negotiate my Abraxane dose down a bit going forward.

    Z

    · Share on Facebook
  • marijen
    marijen
    edited May 2018

    Thanks for posting "Breast Cancer Scrubbed from Government Website", Hopeful, wtf? That was over 5 months ago. Where's Joe Biden and the Moonshot?

    · Share on Facebook
  • marijen
    marijen
    edited May 2018

    Fifteen Things Physicians and Patients Should Question


    https://www.aafp.org/dam/AAFP/documents/about_us/i...





    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    'World-first' call for exercise to be prescribed to all Australian cancer patients

    http://www.abc.net.au/news/2018-05-07/cancer-patients-engaging-in-exercise-show-improvement/9733882?mc_cid=fab8282695&mc_eid=12d673e585

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Obamacare Premiums to Surge Next Year, Early Requests Show

    https://www.bloomberg.com/news/articles/2018-05-07...

    {disturbing}

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Global Analysis of Advanced/Metastatic Breast Cancer: Decade Report (2005–2015)


    TAKE-HOME MESSAGE

    • Using results from four global qualitative and quantitative surveys of nearly 15,000 patients in 34 countries as well as a literature review, the authors provide an overview of metastatic breast cancer care gaps, resources, and support available for patients in different regions of the world. Modest outcome improvements have been reported over the last decade. However, patients still do not receive adequate information. Furthermore, quality of life may have declined over the past decade.
    • A global effort of healthcare professionals, patients, families, and advocates is needed to improve patient outcomes and quality of life.

    https://www.practiceupdate.com/c/67169/67/13/?elsc...


    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Time Trends of Overall Survival Among Metastatic Breast Cancer Patients in the Real-Life ESME Cohort


    TAKE-HOME MESSAGE

    • In this French, multicenter observational cohort of 15,085 patients with newly diagnosed metastatic breast cancer and full immunohistochemistry data, the authors evaluated the impact of year of diagnosis on overall survival. Of these patients, 9907 were HR+/HER2−, 2861 were HER2+, and 2317 were HR−/HER2−. The entire cohort had a median overall survival of 37.22 months. Year of diagnosis, age, subtype, disease-free interval, visceral metastases, and number of involved organs were independent predictors of overall survival. Year of diagnosis was a strong predictor of overall survival in HER2+ patients, but not in HR+/HER2− or HR−/HER2− patients.
    • These data demonstrate improved overall survival in patients with HER2+ metastatic breast cancer, highlighting the need for new strategies for other subtypes.
    • RESULTS: Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P < .001), but not in HR+/HER2- nor HR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00 [95% CI, 0.97-1.02], P = .90, respectively).

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Intrathecal Administration of Trastuzumab Is Feasible in Patients With HER2+ Breast Carcinomatous Meningitis


    TAKE-HOME MESSAGE

    • In this phase I dose-escalation study, 16 patients with leptomeningeal carcinomatosis from HER2+ breast cancer received intrathecal trastuzumab. No dose-limiting toxicity of trastuzumab was observed. Of these patients, 11 did not exhibit toxicities attributable to trastuzumab. Minor toxicities attributable to trastuzumab at 60-mg or higher dose levels included headache, nausea, vomiting, cervical pain, and peripheral neuropathy. Clinical responses were achieved in 3 patients, 7 had stable disease, and 4 had progressive disease.
    • The recommended phase II weekly dose of intrathecal trastuzumab is 150 mg in patients with HER2+ breast cancer.

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    A Serum MicroRNA Signature Predicts Trastuzumab Benefit in HER2+ MBC


    TAKE-HOME MESSAGE

    • In this study, a miRNA microarray identified 13 miRNAs in the serum of patients with HER2+ metastatic breast cancer with a distinct response to trastuzumab treatment. Of these, four miRNAs (miR-940, miR-451a, miR-16-5p, and miR-17-3p) were used to create a signature predictive of survival using a LASSO model. These miRNAs are directly involved in regulating resistance to trastuzumab.
    • This miRNA signature, which may predict trastuzumab benefit in patients with HER2+ metastatic breast cancer, warrants further validation in prospective clinical trials.

    https://www.practiceupdate.com/c/67476/67/13/?elsc...

    Abstract - Published: 24 April 2018:

    https://www.nature.com/articles/s41467-018-03537-w

    {This study was done in China. It's very new. Really interesting, IMO. Would be interested to hear if anyone's MO team has mentioned this in discussion. Thx.}

    · Share on Facebook
  • zarovka
    zarovka
    edited May 2018

    Lumpie - fascinating series of posts. Z

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Hopeful8201: Thanks for posting about "Breast Cancer Info Scrubbed From Government Website." That is, indeed, disturbing.

    https://www.medscape.com/viewarticle/894784?src=WN...

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Pressure to stay positive may be a negative for cancer patients

    https://www.theguardian.com/society/2018/may/15/pr...

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Exploring vitamin D metabolism and function in cancer

    https://www.nature.com/articles/s12276-018-0038-9

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    "The All of Us Research Program has a simple mission. We want to speed up health research breakthroughs. To do this, we're asking one million people to share health information. In the future, researchers can use this to conduct thousands of health studies."

    https://www.joinallofus.org/en


    · Share on Facebook
  • Amelia01
    Amelia01
    edited May 2018

    I can't recall if we shared this before, but this would be a great tool for all surgeries! I wonder if any of our members have participated with a trial.

    Light up malignant cells during surgery with infrared lighting.

    https://www.statnews.com/2018/03/14/cancer-tumors-...

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. pub date: 2018 Apr 11

    Abstract:

    https://www.ncbi.nlm.nih.gov/pubmed/29643230

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    UTA researcher patents "roach motel" for cancer

    https://www.uta.edu/news/releases/2018/05/Tang%20C...

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Invasive cancers that are born to be bad show detectable differences from harmless tumors

    https://www.news-medical.net/amp/news/20180515/Inv...

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    ASCO: 2018 Treatment Algorithm for Metastatic HER2-Positive Breast Cancer

    http://www.ascopost.com/issues/april-25-2018/2018-...

    · Share on Facebook
  • couragement
    couragement
    edited May 2018

    Hi Lumpie,

    Thank you so much for all your work in posting these studies. I greatly appreciate it. How are you doing and feeling these days?

    May you be well.

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Hi couragement! I'm a little obsessive (but also a little random) with the research and reading... and how much I can do varies with my workload... but if I am finding interesting stuff, I figure I might as well share it!

    I had an infusion yesterday. The last couple of times I have been so tired, i slept through 90% of it... which is not bad. Besides some fatigue and a few misc side effects, I am doing pretty well these days - thanks for asking. I have a scan coming up. Fingers crossed. Hope you are doing well. Thanks for reading. If you find any interesting articles, please share.

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Israeli researchers say they have found a way to curb growth of cancer cells

    https://www.timesofisrael.com/israel-researchers-s...

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Glyphosate shown to disrupt microbiome 'at safe levels', study claims

    Study on rats said to show that the chemical, found in Monsanto's Roundup weedkiller, poses 'a significant public health concern'

    https://www.theguardian.com/environment/2018/may/1...

    {troubling}

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    Study Finds More Isn't Better for Widely Used Breast Cancer Drug

    ...women with a dangerous form of breast cancer have relied on Roche Holding AG's blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. A new study finds that they may be able to cut their treatment in half.

    https://www.bloomberg.com/news/articles/2018-05-16...

    Same topic, NY Times:

    https://mobile.nytimes.com/2018/05/16/health/breas...


    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    This new beer is developed specifically for breast cancer patients

    https://www.fastcompany.com/40572691/this-new-beer...

    {Wonder if they'd wanna fund some meaningful research....?}

    · Share on Facebook
  • Lumpie
    Lumpie
    edited May 2018

    When Doctors Downplay Women's Health Concerns

    https://www.nytimes.com/2018/05/03/well/live/when-...


    · Share on Facebook

Categories